Brief: Prelude Announces Dosing Of First Patient In Phase 1 Trial Of Mcl1 Inhibitor PRT1419
30/09/2020 12:17
Sept 30 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE
1 TRIAL OF MCL1 INHIBITOR PRT1419 FOR THE TREATMENT OF
RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
Source text for Eikon: ID:nGNXbVvfGd
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview